Supporting Information

Compounded Formulations of Dimethyl Fumarate Show Significant Variability in Product Characteristics

Author
P. Boulas

Affiliation
1Biogen, Cambridge, MA, USA

*Correspondence
P. Boulas
Biogen
105 Broadway
Cambridge, MA 02142
USA
Tel.: +1/617/914 0809
Fax: +1/617/679 6200
Email: Pierre.Boulas@biogen.com
Supplemental Figure 1. Impurity profile of \textbf{a} cDMF-A and \textbf{b} cDMF-B.

DMF, dimethyl fumarate; MHF, methyl hydrogen fumarate.
Underline indicates impurities present at 0.2\% or more.
Supplemental Figure 2. DMF and EHF capsule-to-capsule variability content in 40 samples of cFumaderm.

DMF, dimethyl fumarate; EHF, ethyl hydrogen fumarate.
Circle represents label listed dose: 120mg DMF/84 mg EHF (as mixture of Ca, Mg and Zn salts).
Supplemental Figure 3. Graphical representation of average in vitro release tests for multiple capsules cFumaderm a over the time course of 260 min and after b 4 h (2 h in SGF; 2 h in SIF) from 18 capsules of cFumaderm.

(a) Time-course analysis

(b) Release after 4 hours

DMF, dimethyl fumarate; EHF, ethyl hydrogen fumarate; SGF, simulated gastric fluid; SIF, simulated intestinal fluid.